CCMU
ALPN

Cheyne Capital Management (UK)’s Alpine Immune Sciences Inc ALPN Stock Holding History

Cheyne Capital Management (UK)’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-181,886
Closed -$1.34M – 57
2022
Q4 		$1.34M Buy
+181,886
New +$1.16M 2.34% 11

Other funds holding ALPN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Cheyne Capital Management (UK)'s ALPN Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2023, closing a stake of 181,886 shares — an estimated $1.34M sold.

Cheyne Capital Management (UK) first reported a position in ALPN in Q4 2022 and held it in 1 quarter. The position peaked at $1.34M in Q4 2022. 60 funds tracked by Wall St. Rank hold ALPN as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Alpine Immune Sciences Inc position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 181,886 Alpine Immune Sciences Inc shares in Q1 2023, an estimated $1.34M.
  • Cheyne Capital Management (UK) first reported a position in Alpine Immune Sciences Inc in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Alpine Immune Sciences Inc position peaked at $1.34M in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.